过去几十年，肥胖的发生率显著增加。肥胖和多种慢性疾病相关，对健康危害巨大。肥胖症对健康的威胁不仅和肥胖程度有关，还和体脂肪分布有关。相比皮下脂肪，内脏脂肪和异位脂肪与肥胖相关的代谢疾病关系更加紧密。肠促胰岛素类药除了降血糖、减重外，还能改善体脂肪分布，因此这类药物是腹型肥胖糖尿病患者较为理想的降糖减重药物和治疗非酒精性脂肪肝的潜在药物。本文综述了肠促胰岛素类药物GLP⁃1受体激动剂和DPP⁃4抑制剂对体脂肪分布的影响。

Over the past decades, the incidence of obesity has significantly increased. Obesity is associated with many chronic diseases and threatens health of people greatly. The threat of obesity to health is not only related to the degree of obesity, but also to the distribution of body fat. As compared with subcutaneous adipose tissue, vis⁃ ceral and ectopic adipose tissues link more closely to obesity⁃related metabolic diseases. Incretin⁃based drugs can improve body fat distribution in addition to lowering blood glucose and losing weight. Therefore, these types of drugs are more ideal for controlling blood glucose level and weight, and they are potential medications for non⁃alcoholic fatty liver disease. This review summarizes the effects of incretin⁃based drugs glucagon⁃like peptide⁃1 receptor ago⁃ nist and dipeptidyl peptidase 4⁃inhibitors on body fat distribution.